De Novo Cardiac Arrhythmia

From HumanResearchWiki

Contents

1 Introduction
2 Clinical Priority and Clinical Priority Rationale by Design Reference Mission
3 Initial Treatment Steps During Space Flight
4 Capabilities Needed for Diagnosis
5 Capabilities Needed for Treatment
6 Associated Gap Reports
7 Other Pertinent Documents
8 List of Acronyms
9 References
10 Last Update

Introduction

Although astronaut populations are extensively screened, episodes of cardiac arrhythmia have occurred in flight. De novo cardiac arrhythmia may manifest from undetected coronary artery disease, patent foramen ovale, metabolic and/or electrolyte abnormalities, extra cardiac electrical pathways, drugs or as a result of electrocution. Spaceflight associated conditions may contribute to the metabolic changes which are inducive for an arrhythmia (e.g. space motion sickness, cardiovascular decompression sickness following depressurization in preparation for an Extravehicular Activity [EVA], increased intracranial pressure, and sleep dysfunction). Limited diagnostic and treatment capabilities are available on the International Space Station (ISS).[1]

Clinical Priority and Clinical Priority Rationale by Design Reference Mission

One of the inherent properties of space flight is a limitation in available mass, power, and volume within the space craft. These limitations mandate prioritization of what medical equipment and consumables are manifested for the flight, and which medical conditions would be addressed. Therefore, clinical priorities have been assigned to describe which medical conditions will be allocated resources for diagnosis and treatment. “Shall” conditions are those for which diagnostic and treatment capability must be provided, due to a high likelihood of their occurrence and severe consequence if the condition were to occur and no treatment was available. “Should” conditions are those for which diagnostic and treatment capability should be provided if mass/power/volume limitations allow. Conditions were designated as “Not Addressed” if no specific diagnostic and/or treatment capability are expected to be manifested, either due to a very low likelihood of occurrence or other limitations (for example, in medical training, hardware, or consumables) that would preclude treatment. Design Reference Missions (DRMs) are proposed future missions designated by a set of assumptions that encompass parameters such as destination, length of mission, number of crewmembers, number of Extravehicular Activities (EVAs), and anticipated level of

<table>
<thead>
<tr>
<th>Design Reference Mission</th>
<th>Clinical Priority</th>
<th>Clinical Priority Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lunar sortie mission</td>
<td>Not Addressed</td>
<td>The relatively short duration of the lunar sortie mission combined with the extensive preflight screening of the crewmembers make the likelihood of a de novo cardiac arrhythmia low. Specific treatment for this medical condition will therefore not be manifested.</td>
</tr>
<tr>
<td>Assumptions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 4 crewmembers (3 males, 1 female)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 14 days total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 4 EVAs/ crewmember</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Level of Care 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunar outpost mission</td>
<td>Shall</td>
<td>The long duration of the lunar outpost mission and the prior occurrence of de novo cardiac arrhythmia in otherwise healthy and well screened crewmembers makes the likelihood of a de novo cardiac arrhythmia higher compared with the shorter duration missions, raising some clinical concern. Therefore, treatment capability shall be manifested.</td>
</tr>
<tr>
<td>Assumptions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 4 crewmembers (3 males, 1 female)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 180 days total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 90 EVAs/ crewmember</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Level of Care 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Near-Earth Asteroid (NEA) mission</td>
<td>Shall</td>
<td>The long duration of the NEA mission and the previous occurrence of de novo cardiac arrhythmia in otherwise healthy and well screened crewmembers makes the likelihood of a de novo cardiac arrhythmia higher compared with shorter duration missions. Therefore, treatment capability shall be manifested.</td>
</tr>
<tr>
<td>Assumptions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3 crewmembers (2 males, 1 female)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 395 days total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 30 EVAs/ crewmember</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Level of Care 5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initial Treatment Steps During Space Flight

A link is provided to a prior version of the International Space Station (ISS) Medical Checklist, which outlines the initial diagnostic and treatment steps recommended during space flight for various conditions which may be encountered onboard the ISS. Further diagnostic and treatment procedures beyond the initial steps outlined in the Medical Checklist are then recommended by the ground-based Flight Surgeon, depending on the clinical scenario.
Please note that this version does not represent current diagnostic or treatment capabilities available on the ISS. While more recent versions of this document are not accessible to the general public, the provided version of the checklist can still provide a general sense of how medical conditions are handled in the space flight environment. Medical Checklists will be developed for exploration missions at a later point in time.

Please note this file is over 20 megabytes (MB) in size, and may take a few minutes to fully download.

ISS Medical Checklist (http://www.nasa.gov/centers/johnson/pdf/163533main_ISS_Med_CL.pdf)

Capabilities Needed for Diagnosis

The following is a hypothetical list of capabilities that would be helpful in diagnosis. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.

- Vital signs measurement capability (blood pressure, pulse, respiratory rate, temperature, pulse oximetry, as required per the patient's clinical state)
- Auscultation device (such as a stethoscope)
- Electrocardiogram [12-lead Electrocardiograph (ECG)]
- Cardiac (ECG) monitor
- Imaging (such as ultrasound)
- Blood analysis (electrolytes, cardiac enzymes)

Capabilities Needed for Treatment

The following is a hypothetical list of capabilities that would be helpful in treatment. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.

- Beta-blockers [oral and intravenous (IV)]
- Adenosine (IV)
- Amiodarone (oral and IV)
- Calcium channel blockers (oral and IV)
- Aspirin (oral)
- Magnesium (IV)
- Cardioversion
- Supplemental oxygen
- IV start and administration kit (rapid access may be needed)

Associated Gap Reports

https://humanresearchwiki.jsc.nasa.gov/index.php?title=De_Novo_Cardiac_Arrhythmia
The NASA Human Research Program (HRP) identifies gaps in knowledge about the health risks associated with human space travel and the ability to mitigate such risks. The overall objective is to identify gaps critical to human space missions and close them through research and development. The gap reports that are applicable to this medical condition are listed below. A link to all of the HRP gaps can be found here (http://humanresearchroadmap.nasa.gov/Gaps/).

1.01 - We do not know which emerging technologies are suitable for preflight medical screening for exploration missions.
2.01 - We do not know the quantified health and mission outcomes due to medical events during exploration missions.
2.02 - We do not know how the inclusion of a physician crew medical officer quantitatively impacts clinical outcomes during exploration missions.
3.01 - We do not know the optimal training methods for in-flight medical conditions identified on the Exploration Medical Condition List taking into account the crew medical officer’s clinical background. (Closed)
3.03 - We do not know which emerging technologies are suitable for in-flight screening, diagnosis, and treatment during exploration missions.
4.01 - We do not have the capability to provide a guided medical procedure system that integrates with the medical system during exploration missions.
4.02 - We do not have the capability to provide non-invasive medical imaging during exploration missions.
4.04 - We do not have the capability to deliver supplemental oxygen to crew members while minimizing local and cabin oxygen build-up during exploration missions.
4.05 - We do not have the capability to measure laboratory analytes in a minimally invasive manner during exploration missions.
4.12 - We do not have the capability to generate and utilize sterile intravenous fluid from potable water during exploration missions.
4.14 - We do not have the capability to track medical inventory in a manner that integrates securely with the medical system during exploration missions.
4.15 - Lack of medication usage tracking system that includes automatic time stamping and crew identification
4.17 - We do not have the capability to package medications to preserve stability and shelf-life during exploration missions.
4.19 - We do not have the capability to monitor physiological parameters in a minimally invasive manner during exploration missions.
4.23 - We do not have the capability to auscultate, transmit, and record body sounds during exploration missions.
4.24 - Lack of knowledge regarding the treatment of conditions on the Space Medicine Exploration Medical Condition List in remote, resource poor environments (Closed)
5.01 - We do not have the capability to comprehensively manage medical data during exploration missions.

Other Pertinent Documents

List of Acronyms

<table>
<thead>
<tr>
<th>D</th>
<th>DRM</th>
<th>Design Reference Mission</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>ECG</td>
<td>Electrocardiograph</td>
</tr>
<tr>
<td></td>
<td>EMCL</td>
<td>Exploration Medical Condition List</td>
</tr>
<tr>
<td></td>
<td>EVA</td>
<td>Extravehicular Activity</td>
</tr>
<tr>
<td>H</td>
<td>HRP</td>
<td>Human Research Program</td>
</tr>
</tbody>
</table>

https://humanresearchwiki.jsc.nasa.gov/index.php?title=De_Novo_Cardiak_Arrhythmia
I
ISS  International Space Station
IV  Intravenous

M
MB  Megabyte

N
NASA  National Aeronautics and Space Administration
NEA  Near Earth Asteroid

U
U.S.  United States

References


Last Update

This topic was last updated on 8/14/2014 (Version 2).

Retrieved from "https://humanresearchwiki.jsc.nasa.gov/index.php?title=De_Novo_Cardiac_Arrhythmia&oldid=5638"

Category: Medical Conditions

- This page was last modified on 12 August 2014, at 14:53.